Skip to main content
. 2023 Nov 3;299(12):105418. doi: 10.1016/j.jbc.2023.105418

Figure 2.

Figure 2

Loss-of-function screen identifies MARK3 and STK10 as potential therapeutic targets. Histogram of cell viability measured by CellTiter-Glo post-siRNA knockdown of 22 candidate kinases in MP38 (left panel) and OMM1.3 (right panel) cells. Targets are ordered based on average cell viability in all three cell lines.